SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Voltaire Synthetic CCD

PatientVoltaire
Date of birth1942-11-21
IdentifiersMRN HR-EN002-SYN; SSN (made up) 000-02-5174
Document date2026-11-01
AuthorHonorine Delacroix-Mensah, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Primary care visit for three weeks of visible blood in the urine and difficult urination at 83. Concerns: Blood in the urine and difficulty passing water for three weeks; afraid it is something serious; Wants to finish the play he is staging and to keep writing, and does not want long stays in hospital; Has always taken many remedies of his own choosing and asks for something strong to make him sleep. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Diphenhydramine 25 mg oral capsule, one capsule at night for sleep (over the counter)One capsule at bedtimeOral route2025-09-01 to 2026-04-06stoppedS
Tamsulosin 0.4 mg oral capsule, one capsule at bedtimeOne capsule 30 minutes after the evening mealOral route2026-04-06activeS
Polyethylene glycol 3350, 17 g in a glass of water once daily17 g dissolved in water once dailyOral route2024-01-15activeS
Cefpodoxime 200 mg oral tablet, one tablet by mouth twice daily for 7 daysOne tablet twice daily with food for 7 daysOral route2026-04-20 to 2026-04-26completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth three times daily (3 g a day)Two tablets three times daily; no more than 3 g a dayOral route2026-04-22activeS
Oxycodone 5 mg oral tablet, one half tablet (2.5 mg) by mouth every 6 hours if needed for bladder pain not relieved by acetaminophen, no more than three doses a day; 15 tablets dispensedHalf a tablet every 6 hours as needed; no more than three half tablets a dayOral route2026-04-22activeS
Sennosides 8.6 mg oral tablet, two tablets at bedtime while taking oxycodoneTwo tablets at bedtimeOral route2026-04-22activeS
Naloxone 4 mg nasal spray, one spray in one nostril for suspected opioid overdose; call 911; may repeat in 2 to 3 minutes in the other nostrilOne spray for suspected overdose; repeat after 2 to 3 minutes if no responseNasal route2026-04-22activeS

Procedures

ProcedureDatesStatusEvidence
Insertion of a 16 Fr two-way indwelling urethral catheter in the clinic: 520 mL of pink urine drained without clots2026-04-06 to 2026-04-06completedS
Multiphasic CT urography: 4.2 cm sessile soft-tissue mass of the posterior bladder wall extending to the dome, with wall thickening to 1.8 cm and perivesical fat stranding (suspected extravesical extension); no hydronephrosis; upper tracts clear; prostate about 78 mL with a median lobe; no enlarged pelvic or retroperitoneal nodes; no bone lesions2026-04-08 to 2026-04-08completedS
CT of the chest with contrast, done with the urography: no lung nodule, mass, or mediastinal lymph node; airways clear; no source for the earlier bleeding from the mouth2026-04-08 to 2026-04-08completedS
Flexible cystoscopy by urology: solid, sessile, partly necrotic tumor about 4 cm on the posterior wall extending to the dome, with surrounding white keratinizing plaques; trilobar prostatic enlargement with friable surface vessels; catheter replaced2026-04-13 to 2026-04-13completedS
Transurethral resection of the bladder tumor with examination under anesthesia: a mobile, palpable mass (cT3b); resection to muscle. Pathology: keratinizing squamous cell carcinoma, moderately differentiated, invading the muscularis propria, with lymphovascular invasion; no urothelial carcinoma component and no carcinoma in situ; catheter left for drainage2026-04-15 to 2026-04-15completedS
Change of the urethral catheter at the sick visit, with a urine culture from the new catheter2026-04-20 to 2026-04-20completedS
Trial without catheter on tamsulosin: voided 260 mL with a post-void residual of 140 mL2026-04-22 to 2026-04-22completedS
CT of the bladder for radiotherapy planning2026-04-27 to 2026-04-27completedS
Hypofractionated external beam radiotherapy to the bladder, 36 Gy in six weekly fractions of 6 Gy, with daily image guidance, by the radiation oncology team; fractions 1 and 2 given by the last visit2026-04-29in-progressS

Immunizations

DateVaccineStatusEvidence
2025-10-07Influenza vaccine, high dose, 2025-2026 seasoncompletedS
2024-11-12Pneumococcal conjugate vaccine PCV20completedS
2021-06-03Recombinant zoster vaccine, two-dose series completedcompletedS
2019-02-18Tdap vaccinecompletedS
2024-10-01Respiratory syncytial virus vaccine, single dosecompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
4 November 1723Smallpox at 28, with two days of fever and then an eruption, treated with bleeding, emetics, and large amounts of lemonade; out of danger in eleven daysD (CLM-0003)
1769 and throughout his lifeLifelong digestive complaints, colic, and frequent self-treatment with purges and enemas; complaints of the kidneys and bladder; a feeble constitution by his own accountD (CLM-0004)
25 February 1778Sudden bleeding from the mouth and nose after a fit of coughing, continuing for several days, six weeks before the index visit; source not establishedD (CLM-0006)

Family History

RelativeConditionAge at deathEvidence
motherDied when he was seven; cause not recorded in the cited sourceD (CLM-0001)
fatherA receiver in the audit office; his health and cause of death are not recorded in the cited sourcesD (CLM-0001)

Health Concerns

ConcernStatusEvidence
Blood in the urine and difficulty passing water for three weeks; afraid it is something seriousactiveS
Wants to finish the play he is staging and to keep writing, and does not want long stays in hospitalactiveS
Has always taken many remedies of his own choosing and asks for something strong to make him sleepactiveS

Assessment

Most recent measures: Erythrocytes [#/area] in Urine sediment by Microscopy high power field 75 on 2026-04-06; Leukocytes [#/area] in Urine sediment by Microscopy high power field 60 on 2026-04-20; International Prostate Symptom Score [IPSS] 15 on 2026-05-06; US Urinary bladder Volume post void 120 on 2026-05-06; Hemoglobin [Mass/volume] in Blood 10.8 on 2026-05-06; Leukocytes [#/volume] in Blood by Automated count 6.9 on 2026-05-06; Platelets [#/volume] in Blood by Automated count 231 on 2026-05-06; Sodium [Moles/volume] in Serum or Plasma 138 on 2026-04-06; Potassium [Moles/volume] in Serum or Plasma 4.4 on 2026-05-06; Carbon dioxide, total [Moles/volume] in Serum or Plasma 21 on 2026-04-06; Urea nitrogen [Mass/volume] in Serum or Plasma 22 on 2026-04-13; Creatinine [Mass/volume] in Serum or Plasma 1.2 on 2026-05-06; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 60 on 2026-05-06; Glucose [Mass/volume] in Serum or Plasma 96 on 2026-04-06; Prostate specific Ag [Mass/volume] in Serum or Plasma 6.4 on 2026-04-06; Pain severity - 0-10 verbal numeric rating [Score] - Reported 2 on 2026-05-06; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-04-28; Total score [Mini-Cog] 4 on 2026-04-28 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Visible blood in the urine for three weeks with clots, and a weak stream, straining, and frequent small voids, in a man of 83; under evaluationresolvedconfirmed R31.0S — Synthetic presenting problem echoing his documented urinary complaints and last illness; superseded by the diagnosis at the third chronic-care visit.
Chronic urinary retention with overflow (post-void residual 460 mL at intake), worsened by a nightly anticholinergic sleep aid; drained by an indwelling catheteractiveconfirmed R33.8S — Synthetic finding echoing the strangury and catheterization documented in his last weeks.
Acute kidney injury from bladder outlet obstruction (creatinine 1.68 mg/dL, from 1.1 mg/dL a year earlier)resolvedconfirmed N17.9S — Synthetic finding; it echoes, without asserting, the later encyclopedia term uremia.
Benign prostatic hyperplasia with lower urinary tract symptoms: prostate about 78 mL on CT, enlarged, firm, and smooth on examination, PSA 6.4 ng/mL with a PSA density of 0.08; no prostate biopsy, by shared decisionactiveconfirmed N40.1S — Synthetic diagnosis echoing the very large prostate described at the 1778 autopsy; whether that prostate was malignant is unknown (CLM-0012).
Squamous cell carcinoma of the bladder, keratinizing, posterior wall extending to the dome, muscle-invasive with extravesical extension (clinical stage cT3b N0 M0, stage IIIA), pure squamous histology without a urothelial component; treated with palliative-intent hypofractionated radiotherapy by shared decisionactiveconfirmed C67.4S — Synthetic modern diagnosis confirmed by resection pathology. His bladder disease at autopsy is documented (D); calling it squamous cell carcinoma is a 2025 retrospective interpretation (R, disputed).
Chronic constipation, lifelong by his account, with long use of laxatives and self-given enemasactiveconfirmed K59.09S — Synthetic modern problem echoing his documented colic, purges, and enemas; no diagnosis of inflammatory bowel disease is made.
Febrile catheter-associated urinary tract infection with Escherichia coli, five days after bladder tumor resection; treated with cefpodoxime and a catheter change; resolvedresolvedconfirmed T83.511AS — Synthetic intercurrent infection; it echoes, without asserting, the infected urine described in his last weeks (CLM-0009).

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-06Erythrocytes [#/area] in Urine sediment by Microscopy high power field75/[HPF]0 to 2 per high-power field; 3 or more is microhematuria (AUA/SUFU)HighS
2026-04-06Leukocytes [#/area] in Urine sediment by Microscopy high power field8/[HPF]<=5 /[HPF]HighS
2026-04-06International Prostate Symptom Score [IPSS]22{score}S
2026-04-06US Urinary bladder Volume post void460mLBelow 100 mL; 300 mL or more suggests chronic retentionHighS
2026-04-06Hemoglobin [Mass/volume] in Blood11.6g/dL13.2-16.6 g/dLLowS
2026-04-06Leukocytes [#/volume] in Blood by Automated count7.810*3/uL3.4-9.6 10*3/uLNormalS
2026-04-06Platelets [#/volume] in Blood by Automated count26810*3/uL150-400 10*3/uLNormalS
2026-04-06Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-04-06Potassium [Moles/volume] in Serum or Plasma5mmol/L3.5-5.1 mmol/LNormalS
2026-04-06Carbon dioxide, total [Moles/volume] in Serum or Plasma21mmol/L22-29 mmol/LLowS
2026-04-06Urea nitrogen [Mass/volume] in Serum or Plasma34mg/dL8-24 mg/dLHighS
2026-04-06Creatinine [Mass/volume] in Serum or Plasma1.68mg/dL0.74-1.35 mg/dLHighS
2026-04-06Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M40mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-04-06Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
2026-04-06Prostate specific Ag [Mass/volume] in Serum or Plasma6.4ng/mL<=4 ng/mLHighS
2026-04-13Hemoglobin [Mass/volume] in Blood11.2g/dL13.2-16.6 g/dLLowS
2026-04-13Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-04-13Urea nitrogen [Mass/volume] in Serum or Plasma22mg/dL8-24 mg/dLNormalS
2026-04-13Creatinine [Mass/volume] in Serum or Plasma1.24mg/dL0.74-1.35 mg/dLNormalS
2026-04-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M58mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-04-20Leukocytes [#/area] in Urine sediment by Microscopy high power field60/[HPF]<=5 /[HPF]HighS
2026-04-20Leukocytes [#/volume] in Blood by Automated count12.610*3/uL3.4-9.6 10*3/uLHighS
2026-04-20Creatinine [Mass/volume] in Serum or Plasma1.34mg/dL0.74-1.35 mg/dLNormalS
2026-04-20Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M53mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-04-20Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
2026-04-22Hemoglobin [Mass/volume] in Blood10.9g/dL13.2-16.6 g/dLLowS
2026-04-22Leukocytes [#/volume] in Blood by Automated count8.210*3/uL3.4-9.6 10*3/uLNormalS
2026-04-22Platelets [#/volume] in Blood by Automated count25410*3/uL150-400 10*3/uLNormalS
2026-04-22Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-04-22Creatinine [Mass/volume] in Serum or Plasma1.22mg/dL0.74-1.35 mg/dLNormalS
2026-04-22Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M59mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-04-22US Urinary bladder Volume post void140mLBelow 100 mL; 300 mL or more suggests chronic retentionHighS
2026-04-22International Prostate Symptom Score [IPSS]14{score}S
2026-04-22Pain severity - 0-10 verbal numeric rating [Score] - Reported5{score}S
2026-04-28Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-04-28Total score [Mini-Cog]4{score}S
2026-05-06Hemoglobin [Mass/volume] in Blood10.8g/dL13.2-16.6 g/dLLowS
2026-05-06Leukocytes [#/volume] in Blood by Automated count6.910*3/uL3.4-9.6 10*3/uLNormalS
2026-05-06Platelets [#/volume] in Blood by Automated count23110*3/uL150-400 10*3/uLNormalS
2026-05-06Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-05-06Creatinine [Mass/volume] in Serum or Plasma1.2mg/dL0.74-1.35 mg/dLNormalS
2026-05-06Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M60mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-05-06US Urinary bladder Volume post void120mLBelow 100 mL; 300 mL or more suggests chronic retentionHighS
2026-05-06International Prostate Symptom Score [IPSS]15{score}S
2026-05-06Pain severity - 0-10 verbal numeric rating [Score] - Reported2{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-04-06Body height170cmS
2026-04-06Body weight54.2kgS
2026-04-06Body mass index (BMI) [Ratio]18.8kg/m2S
2026-04-06Systolic blood pressure138mm[Hg]S
2026-04-06Diastolic blood pressure72mm[Hg]S
2026-04-06Heart rate84/minS
2026-04-06Respiratory rate16/minS
2026-04-06Body temperature36.7CelS
2026-04-06Oxygen saturation in Arterial blood by Pulse oximetry96%S
2026-04-13Body height170cmS
2026-04-13Body weight54kgS
2026-04-13Body mass index (BMI) [Ratio]18.7kg/m2S
2026-04-13Systolic blood pressure132mm[Hg]S
2026-04-13Diastolic blood pressure70mm[Hg]S
2026-04-13Heart rate80/minS
2026-04-13Respiratory rate16/minS
2026-04-13Body temperature36.6CelS
2026-04-13Oxygen saturation in Arterial blood by Pulse oximetry96%S
2026-04-20Body height170cmS
2026-04-20Body weight53.6kgS
2026-04-20Body mass index (BMI) [Ratio]18.5kg/m2S
2026-04-20Systolic blood pressure118mm[Hg]S
2026-04-20Diastolic blood pressure64mm[Hg]S
2026-04-20Heart rate98/minS
2026-04-20Respiratory rate18/minS
2026-04-20Body temperature38.4CelS
2026-04-20Oxygen saturation in Arterial blood by Pulse oximetry95%S
2026-04-22Body height170cmS
2026-04-22Body weight53.4kgS
2026-04-22Body mass index (BMI) [Ratio]18.5kg/m2S
2026-04-22Systolic blood pressure124mm[Hg]S
2026-04-22Diastolic blood pressure68mm[Hg]S
2026-04-22Heart rate82/minS
2026-04-22Respiratory rate16/minS
2026-04-22Body temperature36.9CelS
2026-04-22Oxygen saturation in Arterial blood by Pulse oximetry96%S
2026-04-28Body height170cmS
2026-04-28Body weight53.5kgS
2026-04-28Body mass index (BMI) [Ratio]18.5kg/m2S
2026-04-28Systolic blood pressure126mm[Hg]S
2026-04-28Diastolic blood pressure70mm[Hg]S
2026-04-28Heart rate78/minS
2026-04-28Respiratory rate16/minS
2026-04-28Body temperature36.6CelS
2026-04-28Oxygen saturation in Arterial blood by Pulse oximetry96%S
2026-05-06Body height170cmS
2026-05-06Body weight53kgS
2026-05-06Body mass index (BMI) [Ratio]18.3kg/m2S
2026-05-06Systolic blood pressure122mm[Hg]S
2026-05-06Diastolic blood pressure68mm[Hg]S
2026-05-06Heart rate80/minS
2026-05-06Respiratory rate16/minS
2026-05-06Body temperature36.7CelS
2026-05-06Oxygen saturation in Arterial blood by Pulse oximetry96%S

Encounters

DatePurposeStatusProvenance
2026-04-06Primary care visit for three weeks of visible blood in the urine and difficult urination at 83finishedS
2026-04-13One-week review of CT urography and kidney function; urology consultation with office cystoscopyfinishedS
2026-04-22Review of resection pathology, diagnosis, geriatric assessment, trial without catheter, and shared decision on treatmentfinishedS
2026-05-06Two-week review during weekly radiotherapy: symptoms, kidney function, voiding, and opioid safetyfinishedS
2026-04-20Same-day sick visit for fever with a catheter after bladder tumor resectionfinishedS
2026-04-28Subsequent annual wellness visit at 83finishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Hematuria evaluation: urinalysis with microscopy, urine culture, urine cytology, blood count, kidney function, multiphasic CT urography with CT of the chest, and cystoscopycompletedGL-AUA-MH-2025, GL-CMID-2026S
Urology consultation for gross hematuria with chronic retention: cystoscopy, resection if a tumor is found, the voiding trial, and the meaning of the PSAcompletedGL-AUA-MH-2025, GL-CMID-2026, GL-AUA-BPH-2023S
Retention: indwelling catheter now, tamsulosin at bedtime, catheter care teaching, then a trial without catheter with a bladder scan; IPSS and post-void residual at each visitcompletedGL-AUA-BPH-2023, GL-IDSA-CAUTI-2009, GL-CMID-2026S
Medication review: stop the diphenhydramine sleep aid and the over-the-counter sodium phosphate enemas; keep polyethylene glycol; cut coffee to two cups a day, none after noon; sleep advice without sedativescompletedGL-ASCO-GERI-2018, GL-BEERS-2023S
Shared decision on PSA testing: drawn before the catheter to interpret an enlarged, firm prostate, with the understanding that a raised value at 83 would lead to biopsy only if it would change treatmentcompletedGL-AUA-BPH-2023, GL-USPSTF-PSA-2018S
Transurethral resection of the bladder tumor with examination under anesthesia, for diagnosis and stagingcompletedGL-NCCN-BLADDER-2026, GL-AUA-MIBC-2024, GL-EAU-MIBC-2026, GL-CMID-2026S
Geriatric assessment (G8 screen, function, falls, cognition, mood, nutrition, social support, and medicines) before choosing cancer treatmentcompletedGL-ASCO-GERI-2018, GL-BEERS-2023, GL-NCCN-BLADDER-2026S
Shared decision on treatment of muscle-invasive squamous cell carcinoma: radical cystectomy, trimodality bladder preservation, palliative hypofractionated radiotherapy, or symptom care alone; he chose weekly radiotherapy, 36 Gy in six fractions, given by the radiation oncology teamcompletedGL-NCCN-BLADDER-2026, GL-AUA-MIBC-2024, GL-EAU-MIBC-2026, GL-CMID-2026, GL-HYBRID-2017S
Pain plan: scheduled acetaminophen; oxycodone 2.5 mg only if needed, no more than three doses a day, 15 tablets at a time from one prescriber; naloxone nasal spray; senna; the state prescription monitoring program checked; no alcohol, sleep aids, or anyone else's opium-based remedies; doses kept in a locked box; review within two weekscompletedGL-CDC-OPIOID-2022, GL-BEERS-2023S
Palliative care team joins his care alongside radiotherapy for symptom control, goals of care, and support at homecompletedGL-NCCN-BLADDER-2026, GL-ASCO-GERI-2018S
Advance care planning: name a health care agent and complete a portable medical order reflecting his wishescompletedGL-PREV-2026S

Goals

GoalTargetStatusOutcomeProvenance
Find the cause of the bleeding within three weeks2026-04-22completedCT urography in two days, cystoscopy in one week, resection in nine days; pathology reviewed at sixteen daysS
Relieve the retention and recover kidney function2026-04-22completedCreatinine 1.68 to 1.22 mg/dL; voiding after the trial without catheter with a residual of 140 mLS
Treatment that controls bleeding and local symptoms while keeping him at home and writing2026-05-27activeWeekly radiotherapy under way; no clots or retention since the resection; writing most daysS
Pain at or below 3 of 10 without sedation, falls, or constipation2026-05-27activePain 2 of 10 on scheduled acetaminophen and about one half tablet of oxycodone a day; no sedationS
A written plan for future care, with a named health care agent2026-04-28completedHealth care agent named and a portable medical order completed at the wellness visitS

Functional Status

Mental Status